To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adult Patients With Moderate-to-severe Atopic Dermatitis (AD)

Approximately 40 patients who meet eligibility criteria will undergo baseline assessments and
randomize to receive GBR 830 or placebo. Safety and tolerability of GBR 830 will be evaluated
in patients with AD/eczema.

Inclusion Criteria:

- Male or female, 18 years or older

- Moderate to severe atopic dermatitis that has been present for greater than 1 year
from screening with BSA ≥10%.

Exclusion Criteria:

- Treatment with systemic corticosteroids within 4 weeks before randomization, and
topical steroids/tacrolimus and or/pimecrolimus within 1 week before the randomization
(except emollients, and mild steroids (class 6 or 7)

- Any cell-depleting agents including but not limited to rituximab: within 6 months
prior to the baseline visit or until lymphocyte and CD 19+ lymphocyte counts return to
normal, whichever is longer. Other biologics: within 5 half-lives or 8 weeks prior to
the baseline visit, whichever is longer. Allergen immunotherapy within 6 months before
the baseline visit.

- Patient with history of serious local infection and systemic infection Patient with
history or current evidence of diseases such as tuberculosis, malignant disease, other
inflammatory or autoimmune disease or HIV or Hepatitis B or C positive.

- Pregnant or breast-feeding women or women planning to become pregnant or breastfeed
during the study or unwilling to use adequate birth control, if of reproductive
potential and sexually active